Androgel (Testosterone Gel)

DRUG4 trials

Sponsors

National Institute on Aging (NIA), Solvay Pharmaceuticals, Craig Hospital, University Medical Center Groningen

Conditions

Brain InjuryDepressionDiabetesEndocrine DysfunctionHypogonadismOsteoporosisSarcopeniaTesticular Cancer

Phase 2

Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.

CompletedNCT00104572

National Institute on Aging (NIA)Depression, Diabetes, Hypogonadism +2

Start: 2004-03-31End: 2015-01-31Updated: 2018-11-06

Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes

CompletedNCT00141492

Solvay PharmaceuticalsHypogonadism, Type 2 Diabetes

Start: 2004-10-31End: 2007-06-30Updated: 2015-01-21

Short-term Testosterone Replacement in Testicular Cancer Survivors

CompletedNCT03339635

University Medical Center GroningenTesticular Cancer

Start: 2018-12-21End: 2024-06-26Updated: 2024-07-30

Phase 4

Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy

CompletedNCT01201863

Craig HospitalBrain Injury, Endocrine Dysfunction, Trauma

Start: 2010-09-30End: 2014-07-31Updated: 2021-07-27

Related Papers

Cognitive Impairment in Long-Term Survivors of Testicular Cancer More Than 20 Years after Treatment

Cancers2021-11-129 citations

Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy.

2020-09-1419 citations